DealZone

Deals wrap: Pricing Genzyme

September 29, 2010

A sign points the way to the headquarters of Genzyme in Cambridge, Massachusetts August 3, 2010. REUTERS/Brian Snyder    Sanofi-Aventis is considering whether to raise its $18.5-billion bid for drugmaker Genzyme as soon as next week, Bloomberg said, citing sources. Sanofi has not ruled out a hostile bid but would prefer friendly negotiations, the report said. *View article *View factbox

India’s showpiece IT services companies are scouting for acquisitions in overseas markets as they focus on expanding geographical presence as well as client base to boost growth, Reuters reported from the India Investment Summit in Bangalore. *View article *Full coverage

Companies are flush with cash, financing is cheap and dealmaking has staged a comeback, according to Bloomberg’s third-quarter review of M&A activity. *View Bloomberg article

Want to start your own hedge fund? Vanity Fair offers its own five-step program. *View Vanity Fair article

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/